- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
- How the New York Hedge Funds Lost Their Shirts on Tesla
- What You Wear to the Office Still Matters
Article
Rockwell Medical Run-Up Trade Follows Financing
One trader believes Rockwell shares will rise into clinical trial results expected in July.
08:00AM 05/21/13
Article
Synta Is Run-Up to ASCO Lung Cancer Data
The market overreacted to the resignation of Synta's R&D chief.
10:16AM 05/14/13
Article
Expecting Ziopharm Shares To Run Into Phase III Data At Month's End
Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.
07:00AM 03/04/13
Article
Run-Up Trade Into Dynavax's FDA Approval Decision
Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.
07:00AM 02/13/13
Article
Titan Pharma: Run-Up Trade Into March FDA Panel
I expect traders will get an opportunity to profit from increased focus on Titan through March.
06:03AM 01/31/13
Article
A.P. Pharma Run-Up Trade Into FDA Approval Decision
Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.
08:32AM 01/22/13
Article
Shorting Alexza Pharma On FDA's Adasuve Approval
Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.
07:00AM 12/19/12
Article
Anacor Pharma: Run-Up Trade Into January Trial Data
Anacor will be releasing phase III results for a toenail fungus drug in January.
08:29AM 12/11/12
Article
Hyperion Shares Poised to Run Up Ahead of FDA Decision
FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.
08:00AM 12/05/12
Article
Alexza Pharma: Run-Up Trade Into December's Approval Decisions
Alexza expects US and European regulators to announce approval decisions in December.
08:03AM 11/20/12